Cambridge Healthtech Institute’s 4th Annual
Machine Learning for Protein Engineering Part 2
Demonstrating Value and Putting Theory into Practice
13 November 2025
Cambridge Healthtech Institute's Machine Learning for Protein Engineering Part 2 conference at PEGS Europe examines and measures the real impact of using ML/AI techniques by developing benchmarks, experimental validation, data curation, standards, and controls to guide the process for implementing these tools throughout the drug-discovery and development pipeline. Case studies comparing experimental approaches with computational and machine-learning approaches will shed light on how to adapt and utilise them for discovery, prediction, developability, simulation, and optimisation of biologics.
Coverage will include, but is not limited to:
- Implementing benchmarking, experimental validation, standards, and controls
- Applying ML to developability and optimisation
- Reviewing new findings on protein language models
- Using deep learning across the drug-discovery pipeline
- Learning from case studies in protein design
- Measuring results from ML vs. experimental approaches
- Using AI to derisk antibody and biologic development
- Building the latest generative models for de novo design
- Learning about and incorporating diffusion and other models
The deadline for priority consideration is 28 March 2025.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: